Pharmacological p38 MAPK inhibitor SB203580 enhances AML stem cell line KG1a chemosensitivity to daunorubicin by promoting late apoptosis, cell growth arrest in S-phase, and miR-328-3p upregulation

Sara Bahattab; Ali Assiri; Yazeid Alhaidan; Thadeo Trivilegio; Rehab AlRoshody; Sarah Huwaizi; Bader Almuzzaini; Abir Alamro; Manal Abudawood; Zeyad Alehaideb; Sabine Matou-Nasri

doi:10.1016/j.jsps.2024.102055

Q1 2024

Pharmacological p38 MAPK inhibitor SB203580 enhances AML stem cell line KG1a chemosensitivity to daunorubicin by promoting late apoptosis, cell growth arrest in S-phase, and miR-328-3p upregulation

Sara Bahattab · Ali Assiri · Yazeid Alhaidan · Thadeo Trivilegio · Rehab AlRoshody · Sarah Huwaizi · Bader Almuzzaini · Abir Alamro · Manal Abudawood · Zeyad Alehaideb · Sabine Matou-Nasri

10.1016/j.jsps.2024.102055 388 Views 3 Citations

Citations

388

Views

Abstract not available for this publication.

Cite this Article (APA)

Sara, B., Ali, A., Yazeid, A., Thadeo, T., Rehab, A., Sarah, H., Bader, A., Abir, A., Manal, A., Zeyad, A., Sabine, M. (2024). Pharmacological p38 MAPK inhibitor SB203580 enhances AML stem cell line KG1a chemosensitivity to daunorubicin by promoting late apoptosis, cell growth arrest in S-phase, and miR-328-3p upregulation. Saudi Pharmaceutical Journal. https://doi.org/10.1016/j.jsps.2024.102055